Recent Posts
- Zemcelpro® distribution agreement announced for Argentina, Hong Kong and Singapore
- Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
- Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported at the EBMT 2026 Annual Meeting
- Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
- Zemcelpro® (UM171 Cell Therapy) improved outcomes compared with common graft sources: European real-world evidence
Recent Comments
No comments to show.